Pharmaceutical Industry in the United States 2018
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease.
The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The industry has undergone dramatic structural changes over the past few decades, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.
The pharmaceutical industry is under mounting scrutiny because of rapidly increasing expenditures for drugs in the United States. Drug expenditures are now the fastest-growing component of health care costs, increasing at the rate of about 15 percent per year.
Aruvian Research brings you a complete analysis of the Pharmaceutical Industry in the United States. The report covers a brief profile of the global pharmaceutical industry, an analysis of the US pharmaceutical industry, the US generic drugs industry and the US OTC pharmaceutical industry as well.
The report also analyzes the US pharmaceutical industry through two frameworks – a PEST analysis and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, impact of the Hatch-Waxman Act, and the role of the government in the industry.
Major industry players in the industry are analyzed through an analysis of their business segments, a financial analysis and an in-depth SWOT analysis.
Complete with a comprehensive section on the research and development going on in the US pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about the US Pharmaceutical Industry.
The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The industry has undergone dramatic structural changes over the past few decades, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.
The pharmaceutical industry is under mounting scrutiny because of rapidly increasing expenditures for drugs in the United States. Drug expenditures are now the fastest-growing component of health care costs, increasing at the rate of about 15 percent per year.
Aruvian Research brings you a complete analysis of the Pharmaceutical Industry in the United States. The report covers a brief profile of the global pharmaceutical industry, an analysis of the US pharmaceutical industry, the US generic drugs industry and the US OTC pharmaceutical industry as well.
The report also analyzes the US pharmaceutical industry through two frameworks – a PEST analysis and a Porter’s Five Forces Business Strategy analysis. The report also looks at strategies for market entry, impact of the Hatch-Waxman Act, and the role of the government in the industry.
Major industry players in the industry are analyzed through an analysis of their business segments, a financial analysis and an in-depth SWOT analysis.
Complete with a comprehensive section on the research and development going on in the US pharmaceutical industry, Aruvian’s latest research is a collection of all you need to know about the US Pharmaceutical Industry.
A. EXECUTIVE SUMMARY
B. GLOBAL PHARMACEUTICAL INDUSTRY
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value
B.4 Market Share Analysis
B.5 Industry Forecast
C. ANALYZING THE PHARMACEUTICAL INDUSTRY IN THE US
C.1 Industry Statistics
C.2 Industry Growth by Value Analysis
C.3 Industry Segmentation
C.4 Market Share Analysis
C.5 Industry Forecast
D. ANALYZING THE US GENERICS INDUSTRY
D.1 Industry Definition
D.2 Industry Statistics
D.3 Industry Growth Analysis
D.4 Industry Forecast
E. ANALYZING THE US OTC PHARMACEUTICAL INDUSTRY
E.1 Industry Definition
E.2 Industry Statistics
E.3 Industry Growth by Value Analysis
E.4 Industry Segmentation
E.5 Market Share Analysis
E.6 Industry Forecast
F. US PHARMACEUTICAL INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
F.1 Bargaining Power of Buyers
F.2 Bargaining Power of Suppliers
F.3 Competitive Rivalry in the Industry
F.4 Threat of New Entrants
F.5 Threat of Substitutes
G. US PHARMACEUTICAL INDUSTRY: PEST FRAMEWORK ANALYSIS
G.1 Political Features
G.2 Economic Aspects
G.3 Social Aspects
G.4 Technological Aspects
H. INTERNATIONAL COMPETITION AND ECONOMIC TRENDS IN THE US PHARMA INDUSTRY
H.1 Overall Changes in the Industry
H.2 Consolidation
H.3 Modifications in Geographical Concentrations
H.4 Global Trade and Competition
I. KEY TRENDS IN THE PHARMACEUTICAL SECTOR SUPPLY CHAIN
I.1 Restructuring of the Supply Chain
I.2 Decline of Market Share and Margins
I.3 Decreased Access to Newer Drugs
J. MARKET TRENDS & CHALLENGES
K. RESEARCH AND DEVELOPMENT
K.1 Economics of Innovation
K.2 R&D Process
K.3 New Medicines under Development
K.4 Treatments for Rare Diseases
K.5 Case Study – Personalized Medicines
K.6 Patent Incentives & Cooperation in the Industry
L. PATENTS IN THE US PHARMACEUTICAL INDUSTRY
L.1 Introduction
L.2 Hatch Waxman Provisions
L.3 Patent Protection Regime for Branded Drugs
L.3.1 How to Extend the Exclusivity
L.3.2 Limitations on Multiple 30 Month Stays
L.3.3 Medicare Amendments
L.3.4 Changes in the Medicare Rx Drug Improvement Act
L.4 Looking at Offensive Patenting
L.5 Defensive Patenting
L.6 Conclusion
M. LEADING PLAYERS
M.1 Allergan Plc
M.1.1 Corporate Analysis
M.1.2 Financial Analysis
M.1.3 SWOT Analysis
M.2 GlaxoSmithKline Plc
M.2.1 Corporate Analysis
M.2.2 Financial Analysis
M.2.3 SWOT Analysis
M.3 Johnson & Johnson
M.3.1 Corporate Analysis
M.3.2 Financial Analysis
M.3.3 SWOT Analysis
M.4 Merck & Co., Inc.
M.4.1 Corporate Analysis
M.4.2 Financial Analysis
M.4.3 SWOT Analysis
M.5 Mylan NV
M.5.1 Corporate Analysis
M.5.2 Financial Analysis
M.5.3 SWOT Analysis
M.6 Pfizer Inc.
M.6.1 Corporate Analysis
M.6.2 Financial Analysis
M.6.3 SWOT Analysis
M.7 Teva Pharmaceutical Industries Limited
M.7.1 Corporate Analysis
M.7.2 Financial Analysis
M.7.3 SWOT Analysis
M.8 Sandoz International GmbH
N. GLOSSARY OF TERMS
B. GLOBAL PHARMACEUTICAL INDUSTRY
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value
B.4 Market Share Analysis
B.5 Industry Forecast
C. ANALYZING THE PHARMACEUTICAL INDUSTRY IN THE US
C.1 Industry Statistics
C.2 Industry Growth by Value Analysis
C.3 Industry Segmentation
C.4 Market Share Analysis
C.5 Industry Forecast
D. ANALYZING THE US GENERICS INDUSTRY
D.1 Industry Definition
D.2 Industry Statistics
D.3 Industry Growth Analysis
D.4 Industry Forecast
E. ANALYZING THE US OTC PHARMACEUTICAL INDUSTRY
E.1 Industry Definition
E.2 Industry Statistics
E.3 Industry Growth by Value Analysis
E.4 Industry Segmentation
E.5 Market Share Analysis
E.6 Industry Forecast
F. US PHARMACEUTICAL INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
F.1 Bargaining Power of Buyers
F.2 Bargaining Power of Suppliers
F.3 Competitive Rivalry in the Industry
F.4 Threat of New Entrants
F.5 Threat of Substitutes
G. US PHARMACEUTICAL INDUSTRY: PEST FRAMEWORK ANALYSIS
G.1 Political Features
G.2 Economic Aspects
G.3 Social Aspects
G.4 Technological Aspects
H. INTERNATIONAL COMPETITION AND ECONOMIC TRENDS IN THE US PHARMA INDUSTRY
H.1 Overall Changes in the Industry
H.2 Consolidation
H.3 Modifications in Geographical Concentrations
H.4 Global Trade and Competition
I. KEY TRENDS IN THE PHARMACEUTICAL SECTOR SUPPLY CHAIN
I.1 Restructuring of the Supply Chain
I.2 Decline of Market Share and Margins
I.3 Decreased Access to Newer Drugs
J. MARKET TRENDS & CHALLENGES
K. RESEARCH AND DEVELOPMENT
K.1 Economics of Innovation
K.2 R&D Process
K.3 New Medicines under Development
K.4 Treatments for Rare Diseases
K.5 Case Study – Personalized Medicines
K.6 Patent Incentives & Cooperation in the Industry
L. PATENTS IN THE US PHARMACEUTICAL INDUSTRY
L.1 Introduction
L.2 Hatch Waxman Provisions
L.3 Patent Protection Regime for Branded Drugs
L.3.1 How to Extend the Exclusivity
L.3.2 Limitations on Multiple 30 Month Stays
L.3.3 Medicare Amendments
L.3.4 Changes in the Medicare Rx Drug Improvement Act
L.4 Looking at Offensive Patenting
L.5 Defensive Patenting
L.6 Conclusion
M. LEADING PLAYERS
M.1 Allergan Plc
M.1.1 Corporate Analysis
M.1.2 Financial Analysis
M.1.3 SWOT Analysis
M.2 GlaxoSmithKline Plc
M.2.1 Corporate Analysis
M.2.2 Financial Analysis
M.2.3 SWOT Analysis
M.3 Johnson & Johnson
M.3.1 Corporate Analysis
M.3.2 Financial Analysis
M.3.3 SWOT Analysis
M.4 Merck & Co., Inc.
M.4.1 Corporate Analysis
M.4.2 Financial Analysis
M.4.3 SWOT Analysis
M.5 Mylan NV
M.5.1 Corporate Analysis
M.5.2 Financial Analysis
M.5.3 SWOT Analysis
M.6 Pfizer Inc.
M.6.1 Corporate Analysis
M.6.2 Financial Analysis
M.6.3 SWOT Analysis
M.7 Teva Pharmaceutical Industries Limited
M.7.1 Corporate Analysis
M.7.2 Financial Analysis
M.7.3 SWOT Analysis
M.8 Sandoz International GmbH
N. GLOSSARY OF TERMS
LIST OF FIGURES
Figure 1: Global Pharmaceutical Industry breakup by Regions & Countries (%), 2017
Figure 2: Growth of the Global Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Figure 3: Market Share Analysis of the Global Pharmaceutical Industry (%), 2017
Figure 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2017-2022
Figure 5: Growth of the US Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Figure 6: Share of the US in the Global Pharmaceutical Industry (%), 2017
Figure 7: Market Share Analysis of the US Pharmaceutical Industry (%), 2017
Figure 8: Forecast of the US Pharmaceutical Industry (in USD Billion), 2017-2022
Figure 9: Share of the US in the Global Generics Industry (%), 2017
Figure 10: Growth of the US Generic Drugs Market by Value (in USD Billion), 2013-2017
Figure 11: Volume Growth of the US Generic Drugs Market (in Percentage of Total Pharmaceutical Volume), 2013-2017
Figure 12: Forecast of the US Generic Drugs Industry (in USD Billion), 2017-2022
Figure 13: Volume Forecast of the US Generic Drugs Industry (in Percentage of Total Pharmaceutical Volume), 2017-2022
Figure 14: Growth of the US OTC Pharmaceutical Industry by Value (in USD Million), 2013-2017
Figure 15: Segmentation of the US OTC Pharmaceutical Industry (%), 2017
Figure 16: Share of the US in the Global OTC Pharmaceutical Industry (%), 2017
Figure 17: Market Share Analysis of the US OTC Pharmaceutical Industry (%), 2017
Figure 18: Forecast of the US OTC Pharmaceutical Industry (in USD Million), 2017-2022
Figure 19: Porter's Five Forces Analysis of the US Pharmaceutical Industry
Figure 20: Bargaining Power of Buyers in the US Pharmaceutical Industry
Figure 21: Bargaining Power of Suppliers in the US Pharmaceutical Industry
Figure 22: Competitive Rivalry in the US Pharmaceutical Industry
Figure 23: Threat of New Entrants to the US Pharmaceutical Industry
Figure 24: Threat of Substitutes to the US Pharmaceutical Industry
Figure 25: World Sales of Pharmaceuticals (%), 2017
Figure 26: Revenues & Profitability of Mylan NV, 2010-2014
Figure 1: Global Pharmaceutical Industry breakup by Regions & Countries (%), 2017
Figure 2: Growth of the Global Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Figure 3: Market Share Analysis of the Global Pharmaceutical Industry (%), 2017
Figure 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2017-2022
Figure 5: Growth of the US Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Figure 6: Share of the US in the Global Pharmaceutical Industry (%), 2017
Figure 7: Market Share Analysis of the US Pharmaceutical Industry (%), 2017
Figure 8: Forecast of the US Pharmaceutical Industry (in USD Billion), 2017-2022
Figure 9: Share of the US in the Global Generics Industry (%), 2017
Figure 10: Growth of the US Generic Drugs Market by Value (in USD Billion), 2013-2017
Figure 11: Volume Growth of the US Generic Drugs Market (in Percentage of Total Pharmaceutical Volume), 2013-2017
Figure 12: Forecast of the US Generic Drugs Industry (in USD Billion), 2017-2022
Figure 13: Volume Forecast of the US Generic Drugs Industry (in Percentage of Total Pharmaceutical Volume), 2017-2022
Figure 14: Growth of the US OTC Pharmaceutical Industry by Value (in USD Million), 2013-2017
Figure 15: Segmentation of the US OTC Pharmaceutical Industry (%), 2017
Figure 16: Share of the US in the Global OTC Pharmaceutical Industry (%), 2017
Figure 17: Market Share Analysis of the US OTC Pharmaceutical Industry (%), 2017
Figure 18: Forecast of the US OTC Pharmaceutical Industry (in USD Million), 2017-2022
Figure 19: Porter's Five Forces Analysis of the US Pharmaceutical Industry
Figure 20: Bargaining Power of Buyers in the US Pharmaceutical Industry
Figure 21: Bargaining Power of Suppliers in the US Pharmaceutical Industry
Figure 22: Competitive Rivalry in the US Pharmaceutical Industry
Figure 23: Threat of New Entrants to the US Pharmaceutical Industry
Figure 24: Threat of Substitutes to the US Pharmaceutical Industry
Figure 25: World Sales of Pharmaceuticals (%), 2017
Figure 26: Revenues & Profitability of Mylan NV, 2010-2014
LIST OF TABLES
Table 1: Global Pharmaceutical Industry breakup by Regions & Countries (in USD Billion & %), 2017
Table 2: Growth of the Global Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Table 3: Market Share Analysis of the Global Pharmaceutical Industry (%), 2017
Table 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2017-2022
Table 5: Growth of the US Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Table 6: Share of the US in the Global Pharmaceutical Industry (in USD Billion & %), 2017
Table 7: Forecast of the US Pharmaceutical Industry (in USD Billion), 2017-2022
Table 8: Share of the US in the Global Generics Industry (in USD Billion & %), 2017
Table 9: Growth of the US Generic Drugs Market by Value (in USD Billion), 2013-2017
Table 10: Volume Growth of the US Generic Drugs Market (in Percentage of Total Pharmaceutical Volume), 2013-2017
Table 11: Forecast of the US Generic Drugs Industry (in USD Billion), 2017-2022
Table 12: Volume Forecast of the US Generic Drugs Industry (in Percentage of Total Pharmaceutical Volume), 2017-2022
Table 13: Growth of the US OTC Pharmaceutical Industry by Value (in USD Million), 2013-2017
Table 14: Segmentation of the US OTC Pharmaceutical Industry (in USD Million & %), 2017
Table 15: Share of the US in the Global OTC Pharmaceutical Industry (in USD Million & %), 2017
Table 16: Forecast of the US OTC Pharmaceutical Industry (in USD Million), 2017-2022
Table 17: Innovative Approaches towards New Medicines
Table 18: Orphan Drugs Advance Treatment for Rare Diseases
Table 19: Key Financials of Allergan Plc (in USD Million), 2016-2018
Table 20: Revenues & Profitability of Allergan Plc
Table 21: Key Financials of GlaxoSmithKline Plc (in GBP Thousand), 2014-2017
Table 22: Revenues & Profitability of GlaxoSmithKline Plc (in GBP)
Table 23: Key Financials of Johnson & Johnson (in USD Thousand), 2014-2017
Table 24: Revenues & Profitability of Johnson & Johnson (in USD)
Table 25: Key Financials of Merck & Co., Inc. (in USD Thousand), 2014-2017
Table 26: Revenues & Profitability of Merck & Co., Inc. (in USD)
Table 27: Key Financials of Mylan NV (in USD Million), 2010-2014
Table 28: Key Financials of Pfizer Inc. (in USD Thousand), 2014-2017
Table 29: Revenues & Profitability of Pfizer Inc. (in USD)
Table 30: Key Financials of Teva Pharmaceutical Industries Limited (in USD Thousand), 2014-2017
Table 31: Revenues & Profitability of Teva Pharmaceutical Industries Limited (in USD)
Table 1: Global Pharmaceutical Industry breakup by Regions & Countries (in USD Billion & %), 2017
Table 2: Growth of the Global Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Table 3: Market Share Analysis of the Global Pharmaceutical Industry (%), 2017
Table 4: Forecast of the Global Pharmaceutical Industry (in USD Billion), 2017-2022
Table 5: Growth of the US Pharmaceutical Industry by Value (in USD Billion), 2013-2017
Table 6: Share of the US in the Global Pharmaceutical Industry (in USD Billion & %), 2017
Table 7: Forecast of the US Pharmaceutical Industry (in USD Billion), 2017-2022
Table 8: Share of the US in the Global Generics Industry (in USD Billion & %), 2017
Table 9: Growth of the US Generic Drugs Market by Value (in USD Billion), 2013-2017
Table 10: Volume Growth of the US Generic Drugs Market (in Percentage of Total Pharmaceutical Volume), 2013-2017
Table 11: Forecast of the US Generic Drugs Industry (in USD Billion), 2017-2022
Table 12: Volume Forecast of the US Generic Drugs Industry (in Percentage of Total Pharmaceutical Volume), 2017-2022
Table 13: Growth of the US OTC Pharmaceutical Industry by Value (in USD Million), 2013-2017
Table 14: Segmentation of the US OTC Pharmaceutical Industry (in USD Million & %), 2017
Table 15: Share of the US in the Global OTC Pharmaceutical Industry (in USD Million & %), 2017
Table 16: Forecast of the US OTC Pharmaceutical Industry (in USD Million), 2017-2022
Table 17: Innovative Approaches towards New Medicines
Table 18: Orphan Drugs Advance Treatment for Rare Diseases
Table 19: Key Financials of Allergan Plc (in USD Million), 2016-2018
Table 20: Revenues & Profitability of Allergan Plc
Table 21: Key Financials of GlaxoSmithKline Plc (in GBP Thousand), 2014-2017
Table 22: Revenues & Profitability of GlaxoSmithKline Plc (in GBP)
Table 23: Key Financials of Johnson & Johnson (in USD Thousand), 2014-2017
Table 24: Revenues & Profitability of Johnson & Johnson (in USD)
Table 25: Key Financials of Merck & Co., Inc. (in USD Thousand), 2014-2017
Table 26: Revenues & Profitability of Merck & Co., Inc. (in USD)
Table 27: Key Financials of Mylan NV (in USD Million), 2010-2014
Table 28: Key Financials of Pfizer Inc. (in USD Thousand), 2014-2017
Table 29: Revenues & Profitability of Pfizer Inc. (in USD)
Table 30: Key Financials of Teva Pharmaceutical Industries Limited (in USD Thousand), 2014-2017
Table 31: Revenues & Profitability of Teva Pharmaceutical Industries Limited (in USD)
